{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:44:05Z","timestamp":1793641445879,"version":"4.5.1"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"Supplement_M","license":[{"start":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T00:00:00Z","timestamp":1577750400000},"content-version":"vor","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Heart failure (HF) is the prevailing cause of morbidity and mortality in patients with dilated non-ischaemic cardiomyopathy (DCM) and DCM is one of several causes of HF, with several distinct epidemiological and clinical features which may have important implications for its management and prognosis. This article reviews cardiovascular monitoring of specific characteristics of HF in DCM. DCM is defined as ventricular dilatation and systolic dysfunction in the absence of abnormal loading conditions or significant coronary artery disease, the predominant phenotypes of being HFmrEF or HFrEF. DCM accounts for \u223c40% of all cardiomyopathies but its true prevalence among patients with HFrEF is difficult to ascertain with certainty.<\/jats:p>\n               <jats:p>Compared with patients with other HF aetiologies, individuals with DCM tend to be younger, more likely male and less likely to have associated comorbidities. A genetic aetiology of DCM is deemed responsible for \u223c40% of cases. Confirmation of a specific genetic background is clinically relevant (e.g. Duchene or Backer muscular dystrophies, lamin A\/C mutation), because those patients may be at a high risk of progressive left ventricular dysfunction or conduction system disease and sudden death, prompting early prophylaxis with an implantable cardioverter defibrillator. However, in most instances, HF in DCM has a multifactorial aetiology, with multiple factors needing to be systematically evaluated and\/or monitored, since correction of reversible causes or (e.g. tachycardia-induced cardiomyopathy, alcohol intoxication, iron-overload, cancer therapies etc.) or targeting specific pathophysiological causes could lead to an improvement in clinical status.<\/jats:p>\n               <jats:p>The treatment of DCM encompasses HF-related pharmacological and device therapies, and aetiology-specific treatments. At present, options for aetiology-related therapies are limited, and their effectiveness mostly requires confirmation from larger scale randomized trials. Whether outcomes of patients with HF in DCM differ from those with other HF aetiologies is unresolved. DCM is attributable for &amp;gt;40% of patients receiving mechanical circulatory support for advanced HF and it is the leading indication for heart transplantation. More aetiology-specific information is needed both in the evaluation and treatment of dilated cardiomyopathy.<\/jats:p>","DOI":"10.1093\/eurheartj\/suz212","type":"journal-article","created":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T04:17:49Z","timestamp":1577765869000},"page":"M40-M43","source":"Crossref","is-referenced-by-count":31,"title":["Heart failure in dilated non-ischaemic cardiomyopathy"],"prefix":"10.1093","volume":"21","author":[{"given":"Petar M","family":"Seferovi\u0107","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, Belgrade, Serbia"},{"name":"Serbian Academy of Sciences and Arts, Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marija M","family":"Polovina","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Belgrade, Belgrade, Serbia"},{"name":"Department of Cardiology, Clinical Centre of Serbia, 8 Koste Todorovi\u0107a, 11000 Belgrade, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J S","family":"Coats","sequence":"additional","affiliation":[{"name":"IRCCS San Raffaele Pisana, Via di Val Cannuta 247, 00166 Roma, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,31]]},"reference":[{"key":"2019123104174386000_suz212-B1","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ejhf.1461","article-title":"Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2019123104174386000_suz212-B2","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","article-title":"Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases","volume":"29","author":"Elliott","year":"2007","journal-title":"Eur Heart J"},{"key":"2019123104174386000_suz212-B3","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1093\/eurheartj\/ehv727","article-title":"Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases","volume":"37","author":"Pinto","year":"2016","journal-title":"Eur Heart J"},{"key":"2019123104174386000_suz212-B4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijcard.2010.01.011","article-title":"Heart failure etiology impacts survival of patients with heart failure","volume":"149","author":"Pecini","year":"2011","journal-title":"Int J Cardiol"},{"key":"2019123104174386000_suz212-B5","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jchf.2019.02.015","article-title":"Outcomes and effect of treatment according to etiology in HFrEF: an analysis of PARADIGM-HF","volume":"7","author":"Balmforth","year":"2019","journal-title":"JACC Heart Fail"},{"key":"2019123104174386000_suz212-B6","doi-asserted-by":"crossref","first-page":"e579","DOI":"10.1161\/CIR.0000000000000455","article-title":"Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association","volume":"134","author":"Bozkurt","year":"2016","journal-title":"Circulation"},{"key":"2019123104174386000_suz212-B7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1161\/CIRCGENETICS.113.000374","article-title":"Outcome in phospholamban R14del carriers: results of a large multicentre cohort study","volume":"7","author":"van Rijsingen","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"2019123104174386000_suz212-B8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s10741-009-9156-8","article-title":"Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics","volume":"15","author":"Fayssoil","year":"2010","journal-title":"Heart Fail Rev"},{"key":"2019123104174386000_suz212-B9","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2012.07.072","article-title":"Novel predictors of left ventricular reverse remodeling in individuals with recent-onset dilated cardiomyopathy","volume":"61","author":"Kubanek","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2019123104174386000_suz212-B10","doi-asserted-by":"crossref","first-page":"e1932","DOI":"10.7205\/MILMED-D-17-00017","article-title":"Repeat hospitalizations predict mortality in patients with heart failure","volume":"182","author":"Lin","year":"2017","journal-title":"Mil Med"},{"key":"2019123104174386000_suz212-B11","doi-asserted-by":"crossref","first-page":"1392.","DOI":"10.1002\/ejhf.1216","article-title":"Sex- and age-based differences in the natural history and outcome of dilated cardiomyopathy","volume":"20","author":"Halliday","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2019123104174386000_suz212-B12","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jacc.2011.05.033","article-title":"Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study","volume":"58","author":"McNamara","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2019123104174386000_suz212-B13","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/europace\/euu016","article-title":"New-onset left bundle branch block independently predicts long-term mortality in patients with idiopathic dilated cardiomyopathy: data from the Trieste Heart Muscle Disease Registry","volume":"16","author":"Aleksova","year":"2014","journal-title":"Europace"},{"key":"2019123104174386000_suz212-B14","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1056\/NEJMoa032423","article-title":"Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure","volume":"350","author":"Bristow","year":"2004","journal-title":"N Engl J Med"},{"key":"2019123104174386000_suz212-B15","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1136\/hrt.2011.225789","article-title":"Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy","volume":"97","author":"Rossi","year":"2011","journal-title":"Heart"},{"key":"2019123104174386000_suz212-B16","doi-asserted-by":"crossref","first-page":"2307.","DOI":"10.1056\/NEJMoa1806640","article-title":"Transcatheter mitral-valve repair in patients with heart failure","volume":"379","author":"Stone","year":"2018","journal-title":"N Engl J Med"},{"key":"2019123104174386000_suz212-B17","doi-asserted-by":"crossref","first-page":"4277","DOI":"10.1093\/eurheartj\/ehy626","article-title":"Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry","volume":"39","author":"Zafrir","year":"2018","journal-title":"Eur Heart J"},{"key":"2019123104174386000_suz212-B18","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1707855","article-title":"Catheter ablation for atrial fibrillation with heart failure","volume":"378","author":"Marrouche","year":"2018","journal-title":"N Engl J Med"},{"key":"2019123104174386000_suz212-B19","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/eurjhf\/hfs026","article-title":"Gender and survival in patients with heart failure: interactions with diabetes and aetiology. Results from the MAGGIC individual patient meta-analysis","volume":"14","author":"Martinez-Selles","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"2019123104174386000_suz212-B20","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1016\/j.jacc.2010.11.030","article-title":"Prevalence and prognostic significance of left ventricular reverse remodeling in dilated cardiomyopathy receiving tailored medical treatment","volume":"57","author":"Merlo","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"2019123104174386000_suz212-B21","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/ejhf.1531","article-title":"Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology","volume":"21","author":"Seferovic","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2019123104174386000_suz212-B22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609758","article-title":"Declining risk of sudden death in heart failure","volume":"377","author":"Shen","year":"2017","journal-title":"N Engl J Med"},{"key":"2019123104174386000_suz212-B23","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0735-1097(02)02968-6","article-title":"Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study","volume":"41","author":"Felker","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2019123104174386000_suz212-B24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0140-6736(18)32484-X","article-title":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial","volume":"393","author":"Halliday","year":"2019","journal-title":"Lancet"},{"key":"2019123104174386000_suz212-B25","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1093\/eurheartj\/ehx355","article-title":"Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study","volume":"38","author":"Hilfiker-Kleiner","year":"2017","journal-title":"Eur Heart J"},{"key":"2019123104174386000_suz212-B26","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/eurheartj\/ehp249","article-title":"Randomized study on the efficacy of immunosuppressive therapy in patients with virus-negative inflammatory cardiomyopathy: the TIMIC study","volume":"30","author":"Frustaci","year":"2009","journal-title":"Eur Heart J"},{"key":"2019123104174386000_suz212-B27","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/j.amjcard.2008.07.041","article-title":"Usefulness of immunosuppression for giant cell myocarditis","volume":"102","author":"Cooper","year":"2008","journal-title":"Am J Cardiol"},{"key":"2019123104174386000_suz212-B28","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1093\/eurheartj\/ehx321","article-title":"Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease","volume":"38","author":"Caforio","year":"2017","journal-title":"Eur Heart J"},{"key":"2019123104174386000_suz212-B29","doi-asserted-by":"crossref","first-page":"133.","DOI":"10.3390\/biom8040133","article-title":"Add-on immunoadsorption shortly-after optimal medical treatment further significantly and persistently improves cardiac function and symptoms in recent-onset heart failure\u2014a single center experience","volume":"8","author":"Weinmann","year":"2018","journal-title":"Biomolecules"},{"key":"2019123104174386000_suz212-B30","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.jacc.2006.11.041","article-title":"Associations of gender and etiology with outcomes in heart failure with systolic dysfunction: a pooled analysis of 5 randomized control trials","volume":"49","author":"Frazier","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"2019123104174386000_suz212-B31","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1056\/NEJMoa012175","article-title":"Long-term use of a left ventricular assist device for end-stage heart failure","volume":"345","author":"Rose","year":"2001","journal-title":"N Engl J Med"},{"key":"2019123104174386000_suz212-B32","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1093\/icvts\/ivx201","article-title":"Outcome of heart transplantation after bridge-to-transplant strategy using various mechanical circulatory support devices","volume":"25","author":"Yoshioka","year":"2017","journal-title":"Interact Cardiovasc Thorac Surg"},{"key":"2019123104174386000_suz212-B33","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.healun.2016.08.017","article-title":"The Registry of the International Society for Heart and Lung Transplantation: thirty-third Adult Heart Transplantation Report-2016; Focus Theme: primary Diagnostic Indications for Transplant","volume":"35","author":"Lund","year":"2016","journal-title":"J Heart Lung Transplant"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/21\/Supplement_M\/M40\/31661509\/suz212.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/21\/Supplement_M\/M40\/31661509\/suz212.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T04:17:57Z","timestamp":1577765877000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/21\/Supplement_M\/M40\/5691327"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,1]]},"references-count":33,"journal-issue":{"issue":"Supplement_M","published-online":{"date-parts":[[2019,12,31]]},"published-print":{"date-parts":[[2019,12,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/suz212","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,12]]},"published":{"date-parts":[[2019,12,1]]}}}